Randomized phase II study of the Bruton tyrosine kinase inhibitor acalabrutinib, alone or with pembrolizumab in patients with advanced pancreatic cancer
Michael J. Overman(The University of Texas MD Anderson Cancer Center), Anirban Maitra(The University of Texas Southwestern Medical Center)
Cited by 91